Reify Health
Cloud software and clinical trial infrastructure (StudyTeam, Care Access) that helps biopharma sponsors, research sites and CROs enroll patients and run trials faster.
Reify Health is the parent company of StudyTeam (now StudyTeam by Care Access) and Care Access. StudyTeam is trial enrollment software, and Care Access builds and runs research sites to widen patient access to trials. Customers include biopharma sponsors (Amgen, AstraZeneca and Eli Lilly have used its recruitment tools), research sites and CROs. It raised a $220M round in Aug 2021 at a $2.2B valuation and another $220M Series D in Apr 2022 at a reported $4.8B valuation. Total funding is roughly $480M. Revenue estimates are unreliable: about $189M for 2025 on one source and $25–50M on another.
